Prevalence surveys of healthcare-associated infections: what do they tell us, if anything?  by Humphreys, H. & Smyth, E.T.M.
EDITORIAL 10.1111/j.1469-0691.2005.01273.x
Prevalence surveys of healthcare-associated infections: what do they tell
us, if anything?
H. Humphreys1 and E. T. M. Smyth2
1Department of Clinical Microbiology, Royal College of Surgeons in Ireland and Department of
Microbiology, Beaumont Hospital, Dublin, Ireland and 2Northern Ireland Healthcare Associated
Infection Surveillance Centre (HISC) and Infection Prevention and Control, Department of Bacterio-
logy, The Royal Hospitals, Belfast, UK
ABSTRACT
Prevalence surveys of healthcare-associated infections offer advantages over incidence surveys, including
the relative ease of performance, a reduced requirement for resources, the ability to include increased
numbers of hospitals within a shorter period of time, and the possibility of more rapid data analysis and
feedback. Prevalence surveys have also been shown to be useful in monitoring the effectiveness of
infection control programmes. Prevalence surveys appear to be desirable when ﬁnancial support, and ⁄ or
the will to carry out incidence surveys, is lacking. However, it is imperative that prevalence surveys use
standardised methodology and internationally recognised deﬁnitions of infection.
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Healthcare-associated infection (HCAI) is an
important public health problem worldwide
and is of increasing interest to politicians,
patients and members of the general public.
Assessing the true impact of HCAI is difﬁcult
without the necessary resources and without
careful consideration of the logistics of collecting
the information. Prevalence surveys provide
data regarding patients, at one particular point
in time, and are generally easy to conduct,
relatively inexpensive and are not time-consu-
ming. Incidence surveys, which include sequen-
tial data regarding admissions or discharges to
hospital, are more difﬁcult to perform and more
expensive [1]. Ideally, each hospital should have
a continuous prospective surveillance pro-
gramme assessing all HCAIs, but this is often
not feasible because of inadequate resources.
Nonetheless, basic principles of surveillance and
modest resources can produce surgical site
infection rates for a variety of procedures when
surveys are well-performed [2].
Several published surveys have highlighted
some of the strengths and limitations of HCAI
prevalence surveys. The Second National Preval-
ence Survey of Infection in Hospitals, performed
in the UK and Ireland between May 1993 and July
1994, reported an overall HCAI prevalence rate of
9%, but with a range of 2–29%, and a generally
higher rate in teaching hospitals [3]. However, the
deﬁnitions of infection used were agreed before-
hand by a steering group [4], and were not
necessarily directly comparable to other interna-
tionally agreed deﬁnitions. A prevalence survey
during 1994 of nosocomial infection in 72 selected
hospitals in Germany, representing 4.5% of acute
hospital bed capacity [5], found an overall pre-
valence rate of infection of 3.5%, but only con-
ﬁrmed infections were included. This distinction
may partly explain the relatively low prevalence
rate observed. In a more recent survey from
northern Italy, using CDC deﬁnitions, the overall
prevalence rate was 8.9% [6].
While one-off prevalence surveys do highlight
key issues, repeated prevalence surveys provide
more comprehensive data over time, and can also
be used to monitor the effectiveness of infection
prevention and control programmes [7,8]. Nine
repeated prevalence surveys, performed at
monthly intervals in all surgical units of eight
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medium-sized hospitals in Germany, revealed an
overall HCAI prevalence rate of 4% [9]. The use
of repeated surveys helped deﬁne conﬁdence
intervals for sample numbers, and indicated those
hospitals with signiﬁcantly greater prevalence
rates compared with the mean. Four monthly
prevalence surveys were needed to obtain ade-
quate estimates of the overall prevalence rate of
HCAI in surgical departments, and the report
claimed that the inclusion of microbiological
reports, available later, only contributed to the
detection of an additional ﬁve of 70 infections [9].
Ten annual prevalence surveys were conducted
between 1985 and 1995 in a 900-bed tertiary-care
hospital in Connecticut, USA. The overall pro-
portion of patients with nosocomial infections
showed no signiﬁcant increase during the 10-year
period, although there was a signiﬁcantly
increased rate of bloodstream infection [10]. The
authors were surprised that there was no overall
increase in HCAI, given the increasing complexity
of the patient population, and calculated that each
prevalence survey cost only US $3000 (Euro 2400)
per year.
In Norway, HCAIs were analysed by repeated
point-prevalence studies, four per year, in 14
hospitals [11]. The overall rate of HCAI was 6.5%,
but the rate varied from 1.4% to 11.7%. Infection
rates were lower in smaller hospitals, and there
was also a reduction from 2.4% to 1.7% in urinary
tract infections during the period studied.
There are many reasons for the considerable
variation in prevalence rates for HCAI. These
include different case mixes, differences in the
data collected, different deﬁnitions for detecting
infections, and variations in the period during
which data are collected. During a 7-day pre-
valence survey in 1998 in Switzerland, the overall
prevalence of HCAI was 11.3%, but this varied
from 8.4% in acute wards to 16.4% in chronic-
care units [12]. Patients in sub-acute units or
chronic-care settings had higher infection rates,
even after case-mix adjustment. Pittit et al. [13]
found that the workload nursing score was
associated independently with infections in a
prevalence survey including acute, sub-acute
and chronic-care patients.
The criteria used to deﬁne surgical site infection
can also vary considerably, and may or may not
include the results of microbiological investiga-
tions. In a survey of 5804 surgical wounds, the
mean percentage of wounds classiﬁed as infected
differed substantially depending upon the deﬁni-
tions used [14]. Thus, use of CDC deﬁnitions gave
a rate of 19.2%, compared with 12.3% using the
Nosocomial Infection National Surveillance
Scheme deﬁnitions, and 6.8% when the ASEPSIS
score was used [14].
In a national prevalence survey carried out in
Spain, the day of the week on which the data were
collected was found to inﬂuence the prevalence
rate signiﬁcantly. More than 83% of all data was
collected between Monday and Thursday, giving
an overall prevalence rate of 7.1%. However, the
rate varied from 6.9% on a Wednesday to 7.7%
on a Saturday. Only 6.6% of hospitals managed to
collect all the data on a single day [15].
Prevalence surveys have been used with suc-
cess to document nosocomial infections in seven
Swiss paediatric hospitals [16]. Prevalence rates
for nosocomial infection ranged from 1.4% to
11.8% (mean 6.7%), and it was concluded that
periodic prevalence studies are a simple and cost-
effective method for assessing nosocomial infec-
tion and comparing rates between paediatric
hospitals.
There are a variety of methods for capturing
data, including manual entry, direct entry into a
personal digital assistant, laptop or desktop com-
puter, or optical scanning technology. Optical
scanning technology has the advantages of redu-
cing the costs of clerical time, automated data
entry, and an error rate of < 0.2 errors ⁄ 1000
responses [17,18]. Furthermore, collection of such
data can be integrated with data management
systems within a hospital, and thus other data can
be included.
Despite apparent agreement on the concept of a
prevalence survey, there is considerable variation
in how this is interpreted in practice. To derive a
rate for the prevalence of HCAI, data collection
may take place over many months, in selected
groups of patients, using different deﬁnitions,
and may or may not be repeated at intervals. It is
therefore legitimate to compare rates of infection
over time obtained from repeated prevalence
surveys using the same methodology with
broadly similar patient populations, but it is
unwise to compare rates between different sur-
veys because of the considerable variation in the
methodology used.
It is surely time for all HCAI prevalence
surveys to be performed according to interna-
tionally agreed deﬁnitions, and for the collection
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of data in an institution to be restricted to a single
day. Exceptions to this may include cases of
complex infections, speciﬁc groups of patients, or
situations where data on the prevalence of anti-
biotic-resistant bacteria, e.g., methicillin-resistant
Staphylococcus aureus [19], are being collected,
which is dependent on follow-up laboratory
results. Although HCAI incidence data are often
difﬁcult and time-consuming to collect, it is
theoretically possible to calculate incidence rates
from prevalence data, but this is not recommen-
ded [20–22]. Nevertheless, some authors have
used cumulative estimates of the incidence of
hospital-acquired infections based on prevalence
data, while admitting that the validity of the
predicted cumulative incidence is unknown [23].
Consequently, when prevalence surveys are car-
ried out, they should be performed in a stand-
ardised manner that facilitates direct comparisons
and meaningful results.
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